Open Access
Open access
volume 4 issue 1 pages 1-15

Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates

Publication typeJournal Article
Publication date2021-01-01
scimago Q1
wos Q2
SJR1.314
CiteScore8.4
Impact factor4.5
ISSN25164236
PubMed ID:  33554043
Immunology
Immunology and Allergy
Abstract

Calicheamicin, the payload of the antibody-drug-conjugates (ADCs) gemtuzumab ozogamicin (Mylotarg®) and inotuzumab ozogamicin (Besponsa®), belongs to the class of enediyne natural products. Since the isolation and structural determination of the neocarzinostatin chromophore in 1985, the enediynes have attracted considerable attention for their value as DNA damaging agents in cancer chemotherapy. Due to their non-discriminatory cytotoxicity towards both cancer and healthy cells, the clinical utilization of enediyne natural products relies on conjugation to an appropriate delivery system, such as an antibody. Here, we review the current landscape of enediynes as payloads of first-generation and next-generation ADCs.

Found 
Found 

Top-30

Journals

1
2
Journal of the American Chemical Society
2 publications, 6.25%
Organic Letters
2 publications, 6.25%
Journal of Medicinal Chemistry
2 publications, 6.25%
Proceedings of the National Academy of Sciences of the United States of America
2 publications, 6.25%
Molecules
1 publication, 3.13%
Pharmaceutics
1 publication, 3.13%
Antibiotics
1 publication, 3.13%
Microbial Cell Factories
1 publication, 3.13%
Biotechnology Journal
1 publication, 3.13%
Angewandte Chemie
1 publication, 3.13%
Angewandte Chemie - International Edition
1 publication, 3.13%
ACS Chemical Biology
1 publication, 3.13%
Journal of Organic Chemistry
1 publication, 3.13%
Molecular Pharmaceutics
1 publication, 3.13%
Journal of Industrial Microbiology and Biotechnology
1 publication, 3.13%
Helvetica Chimica Acta
1 publication, 3.13%
Advanced Science
1 publication, 3.13%
Russian Journal of General Chemistry
1 publication, 3.13%
Pediatric Neurology
1 publication, 3.13%
Russian Chemical Reviews
1 publication, 3.13%
International Journal of Molecular Sciences
1 publication, 3.13%
European Journal of Medicinal Chemistry
1 publication, 3.13%
Current Opinion in Chemical Biology
1 publication, 3.13%
Cancer Immunology, Immunotherapy
1 publication, 3.13%
Phytotherapy Research
1 publication, 3.13%
ChemistrySelect
1 publication, 3.13%
JACS Au
1 publication, 3.13%
1
2

Publishers

2
4
6
8
10
American Chemical Society (ACS)
10 publications, 31.25%
Wiley
8 publications, 25%
MDPI
4 publications, 12.5%
Springer Nature
3 publications, 9.38%
Elsevier
3 publications, 9.38%
Proceedings of the National Academy of Sciences (PNAS)
2 publications, 6.25%
Pleiades Publishing
1 publication, 3.13%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 3.13%
2
4
6
8
10
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
32
Share
Cite this
GOST |
Cite this
GOST Copy
Adhikari A. et al. Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates // Antibody Therapeutics. 2021. Vol. 4. No. 1. pp. 1-15.
GOST all authors (up to 50) Copy
Adhikari A., Shen B., Rader C. P. Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates // Antibody Therapeutics. 2021. Vol. 4. No. 1. pp. 1-15.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1093/abt/tbab001
UR - https://academic.oup.com/abt/article/4/1/1/6089012
TI - Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates
T2 - Antibody Therapeutics
AU - Adhikari, Ajeeth
AU - Shen, Ben
AU - Rader, Christoph P.
PY - 2021
DA - 2021/01/01
PB - Oxford University Press
SP - 1-15
IS - 1
VL - 4
PMID - 33554043
SN - 2516-4236
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2021_Adhikari,
author = {Ajeeth Adhikari and Ben Shen and Christoph P. Rader},
title = {Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates},
journal = {Antibody Therapeutics},
year = {2021},
volume = {4},
publisher = {Oxford University Press},
month = {jan},
url = {https://academic.oup.com/abt/article/4/1/1/6089012},
number = {1},
pages = {1--15},
doi = {10.1093/abt/tbab001}
}
MLA
Cite this
MLA Copy
Adhikari, Ajeeth, et al. “Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates.” Antibody Therapeutics, vol. 4, no. 1, Jan. 2021, pp. 1-15. https://academic.oup.com/abt/article/4/1/1/6089012.